Private Eye

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Director buying at NervGen Pharma (V:NGEN)

Updated Monday May 25, 2020 04:16 AM EDT

Brian Eric Bayley, a Director, acquired 100,000 Common Shares on a direct ownership basis at a price of $1.250 through a private transaction on May 20th, 2020. The insider also acquired 100,000 Warrants with an exercise price of $1.600 until May 20, 2022. This represents a $125,000 investment into the company's shares and an account share holdings change of 40.0%.

NervGen Pharma is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

NervGen Pharma Corp. is a Canada-based biotechnology company. The Company is focused on developing solutions for the treatment of nerve damage and neurodegenerative diseases. The Company is also developing drugs for the treatment of spinal cord injury (SCI), multiple sclerosis (MS) and Alzheimer's disease. Its platform technology targets protein tyrosine phosphatase sigma (PTP sigma), a neural receptor that impedes nerve repair. The PTP sigma receptor promote regeneration of damaged nerves, increase plasticity and stimulate remyelination in animal models. The Company's lead product is NVG-291 referred to intracellular signaling peptide (ISP), treatment for SCI and MS.

INK Edge Outlook

CONDITIONS:
Latest
6 months ago
1 year ago
Overall
Mixed
Mixed
Cloudy
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at inkresearch.com.
Two-week free trial for first time users.
Go to NervGen Pharma Corp. (NGEN)'s company page

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Comment On!

No Comments

Twitter

Search (past week) for $NGEN.CA

  • No tweets found

Stocktwits

NervGen Pharma Corp.

  • Symbol not found.